{
  "id": "5c58b99586df2b9174000012",
  "type": "factoid",
  "question": "Cemiplimab is used for treatment of which cancer?",
  "ideal_answer": "Cemiplimab is a PD-1 inhibitor that is approved for treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30456447",
    "http://www.ncbi.nlm.nih.gov/pubmed/30377167",
    "http://www.ncbi.nlm.nih.gov/pubmed/29863979",
    "http://www.ncbi.nlm.nih.gov/pubmed/29934319"
  ],
  "snippets": [
    {
      "text": "PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29863979",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29863979",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29863979",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cemiplimab Approved for Treatment of CSCC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30377167",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The FDA greenlighted the PD-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30377167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cemiplimab Achieves Responses in Cutaneous Squamous Cell Carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29934319",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PD-1 blockade with cemiplimab has antitumor activity with adverse events similar to other PD-1 inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29934319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adverse events that occurred in at least 15% of the patients in the metastatic-disease cohort of the phase 2 study were diarrhea, fatigue, nausea, constipation, and rash; 7% of the patients discontinued treatment because of an adverse event.<br><b>CONCLUSIONS</b>: Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29863979",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA greenlighted the PD-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30377167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma.<br><b>METHODS</b>: We report the results of the phase 1 study of cemiplimab for expansion cohorts of patients with locally advanced or metastatic cutaneous squamous-cell carcinoma, as well as the results of the pivotal phase 2 study for a cohort of patients with metastatic disease (metastatic-disease cohort).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29863979",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "cutaneous squamous cell carcinoma"
}